COPENHAGEN, June 10 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as it tries to ...

COPENHAGEN (Reuters) -Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as it tries to reassure the market of its potential ...

COPENHAGEN (Reuters) -Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug ...

Novo Nordisk (NVO) has initiated a new Phase 3 trial for its next-gen weight loss therapy CagriSema after the Danish drugmaker's REDEFINE 1 Phase 3 trial for the treatment disappointed Wall Street ...

Novo Nordisk continues to pioneer obesity innovation, including presentation of full Phase 3 REDEFINE 1 and 2 trial results, providing insights into the transformational potential of CagriSema ...

The presentation of the CagriSema REDEFINE 1 and 2 trials are the first ever Phase 3 data presented on a GLP-1 and amylin receptor agonist combination, offering insights into the transformational ...

The presentation of the CagriSema REDEFINE 1 and 2 trials are the first ever Phase 3 data presented on a GLP-1 and amylin receptor agonist combination, offering insights into the potential of this ...

"We recognize the complex interplay between cardiovascular and metabolic diseases, including type 2 diabetes and obesity, which require a personalized treatment approach," said Martin Holst Lange ...

Google’s new ‘G’ logo appeared on stage during the I/O 2025 keynote, and is now live in more apps and the web. The new logo made its debut with the Google app on Android and iOS last week.